July 26, 2024 Patient Conference
Join us at our 2024 Patient Conference on July 26th! You will have an opportunity to meet and mingle with patients, as well as learn from top CCM researchers. More…
Patient Participation
Recursion’s REC-994 Trial Fully Enrolled
We are thrilled to announce that the Phase 2 safety trial of Recursion’s REC-994 medicine, being developed specifically for symptomatic CCM, has fully enrolled 60 patients ahead of schedule. Our…
Learn More About Clinical Trials
Learn more about how clinical trials work, check out some Myths vs Facts and get your questions answered with our FAQs. Still have more questions? Reach out at ClinicalTrials@AllianceToCure.org
Atorvastatin Trial Has Completed Enrollment
August 1, 2022 – The atorvastatin experimental proof of concept trial to treat cavernous malformations with symptomatic hemorrhage, hosted at the University of Chicago, has completed enrollment. We congratulate and…
CCM2 exon 2-10 deletion research, led by Alliance to Cure Cavernous Malformation families and Duke University, has identified a new founder mutation. Read coverage in the Atlantic magazine. The collaborative…
